Case Study:
Faster Time to Reimbursement
How to Use AI for Faster Time to Reimbursement
According to Pharmaceutic Executive, a delay in launch can cost a company an average of $15 million per drug, per day. This project was about using Artificial Intelligence to speed up the time to reimbursement on different formularies after FDA approval.
The Client Problem
Thee client analysed how many $ were left on the table with every day delay to reimbursement approval in different formularies. They wanted to see if Artificial Intelligence could impact this positively and speed up time to reimbursement thereby increasing revenue from their products.
The Solution
Using a combination of different AI techniques, to:
- identify the factors affecting time-to-reimbursement for newly launched medicines post market approval,
- provide insight into what to include in, or leave out of submissions for formulary inclusion
- find other important considerations and insights that have worked in the past to accelerate time-to-reimbursement.
The Outcome
Reimbursement was achieved much faster in the pilot of formularies using AI versus the ones not using AI. The average improvement in speed was 6 weeks. At an average of $15 m/day that can be left on the table, the amount of revenue gained from this simple increase in speed to reimbursement allowed a significant return on investment and the approach is now being rolled out to other products as well.
To achieve these kinds of results, contact Eularis today.
Latest Blogs
Check out our latest blogs
How to Spot and Prevent Deepfakes Spreading Medical Misinformation
Back in 2021, many people died and the US economy suffered losses worth $50-300 million each day – both from people refusing to get COVID-19
Multi-Agent Systems: The Limitless Potential of AI Agents in Healthcare and Pharma
Imagine a hospital where all the computer systems can talk to each other seamlessly, schedule appointments, and keep track of medical records without human intervention.
FDA Approved AI: Where Are We Today?
The U.S. Food and Drug Administration regulates certain AI/machine learning-based medical devices through its premarket review and approval pathways. Any software or device that utilizes